Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

NameSilo Technologies Corp. (CSE: URL) (PINKSHEETS: URLOF) (the "Company"), the holding company and majority owner of ...

Curevac N.V. ( (CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. CureVac ...

Guggenheim analyst Seamus Fernandez downgraded GSK (GSK) to Neutral from Buy without a price target following the Q3 report. While the ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

ii This approval underscores GSK's commitment to help drive progress for people living with complex blood cancers.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Haleon missed third-quarter revenue and profit expectations on Thursday, hit by a stronger pound and lower sales of its ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...